Blood monoamines in chronic renal failure: effect of hemodialysis
Abstract
Concentrations of serotonin and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC with ED in platelets and plasma of patients with CRF on program haemodialysis (HD) and in control group. Plasma adrenalin and noradrenalin levels were also determined. A significant decrease in platelet serotonin and an increase in serotonin and 5-HIAA levels in platelet free plasma were found in HD patients compared to control. Dialysis procedures decreased plasma levels of serotonin and 5-HIAA, but did not change platelet serotonin or plasma catecholamines. A correlation between serotonin and catecholamine values was found in HD patients, but not between plasma and platelet serotonin. Possible clinical manifestations of observed changes in blood monoamines are discussed. This work was supported with RFBR Grant 08-04-00951.
About the Authors
M. A. Gilinsky
Institute of Physiology, Siberian Branch of the Russian Academy of Sciences
Russian Federation
Russian Federation
S. I. Anokhin
Siberian Medical Centre of Federal Medical-Biological Agency, Novosibirsk
Russian Federation
Russian Federation
N. A. Zeunova
Siberian Medical Centre of Federal Medical-Biological Agency, Novosibirsk
Russian Federation
Russian Federation
S. A. Koroleva
Siberian Medical Centre of Federal Medical-Biological Agency, Novosibirsk
Russian Federation
Russian Federation
T. V. Latysheva
Institute of Physiology, Siberian Branch of the Russian Academy of Sciences
Russian Federation
Russian Federation
G. M. Petrakova
Institute of Physiology, Siberian Branch of the Russian Academy of Sciences
Russian Federation
Russian Federation
References
1. Гилинский М.А., Латышева Т.В., Семенова Л.П. Определение катехоламинов, серотонина и 5-гидроксииндолуксусной кислоты в одной пробе крови // Клин. лаб. диагностика. 2007. № 6. C. 25–28.
2. Матлина Э.Ш. Обмен катехоламинов в гормональном и медиаторных звеньях симпато-адреналовой системы при стрессе // Усп. физиол. наук. 1972. Т. 3. № 4. С. 92–130.
3. Сидельников Ю.Н., Сиворакша Г.А. Концентрация серотонина в крови больных геморрагической лихорадкой с почечным синдромом // Клин. лаб. диагностика. 1996. № 5. С. 21–22.
4. Федорченко Ю.Л., Давидович И.М. Динамика общего, свободного и тромбоцитарного серотонина в плазме крови больных геморрагической лихорадкой с почечным синдромом // Клиническая медицина. 1990. Т. 68. № 6. С. 62–64.
5. Barisić I., Pivac N., Mück-Seler D., Jakovljević M., Sagud M. Comorbid depression and platelet serotonin in hemodialysis patients // Nephr Clin Pract. 2004. V. 96 (1). P. 10–14.
6. Borgdorff P., Fekkes D., Tangelder G.J. Hypotension caused by extracorporeal circulation: serotonin from pump-activated platelets triggers nitric oxide release. // Circulation. 2002. V. 106 (20). P. 2588–2593.
7. Brewster U.C., Ciampi M.A., Abu-Alfa A.K. et al. Addition of sertraline to other therapies to reduce dialysis-associated hypotension. // Nephrology (Carlton). 2003. V. 8 (6). P. 296–301.
8. Esteve J.M., Launay J.M., Kellermann O. et al. Functions of serotonin in hypoxic pulmonary vascular remodeling // Cell Biochem Biophys. 2007. V. 47 (1). P. 33–44.
9. Euler von U.S., Lundberg U. Quantitation of stress by catecholamine analysis // Clin Pharmacol Ther. 1964. V. 5. P. 398–404.
10. Gritters M., Borgdorff P., Grooteman M.P. et al. Platelet activation in clinical haemodialysis: LMWH as a major contributor to bio-incompatibility? // Nephrol Dial Transplant. 2008. V. 23 (9). P. 2911–2917.
11. Kanai H., Ishii Y., Maezawa A. et al. Serotonin metabolism in patients undergoing hemodialysis // Clin Nephrol. 1996. V. 45 (4). P. 244–249.
12. Kema I.P., de Vries E.G.E., Muskie F.A.J. Clinical chemistry of serotonin and metabolites // J Chromatogr B. 2000. V. 747. P. 33–48.
13. Kerr P.G., Argiles A., Mion C. Whole blood serotonin levels are markedly elevated in patients on dialytic therapy // Am J Nephrol. 1992. V. 12 (1-2). P. 14–18.
14. Kimmel P.L., Cukor D., Cohen S.D. et al. Depression in end-stage renal disease patients: a critical review // Adv Chronic Kidney Dis. 2007. V. 14 (4). P. 328–334.
15. Lechin F., van der Dijs B., Lechin A.E. Circulating serotonin, catecholamines, and central nervous system circuitry related to some cardiorespiratory, vascular, and hematological disorders // J of Appl Res. 2005. V. 5 (4). P. 605–621.
16. Malyszko J., Malyszko J.S., Pawlak D. et al. Hemostatis, platelet function and serotonin in acute and chronic renal failure // Thromb Res. 1996. V. 83. P. 351–361.
17. Oberbeck R. Catecholamines: physiological immunomodulators during health and illness // Curr Med Chem. 2006. V. 13 (17). P. 1979–1989.
18. Picard M., Olichon D., Gombert J. Determination of serotonin in plasma by liquid chromatography with electrochemical detection // J Chromatogr. 1985. V. 341. P. 445–451.
19. Raymond C.B., Wazny L.D., Honcharik P.L. Pharmacotherapeutic options for the treatment of depression in patients with chronic kidney disease // Nephrol Nurs J. 2008. V. 35 (3). P. 257–263.
20. Sebekova K., Spustova V., Opatrny K. Jr. et al. Serotonin and 5-hydroxyindole-acetic acid // Bratisl Lek Listy. 2001. V. 102 (8). P. 351–356.
21. Siddiqui E.J., Thompson C.S., Mikhailidis D.P. et al. The role of serotonin in tumor growth (review) // Oncol Rep. 2005. V. 14. № 6. P. 1593–1597.
22. Sole M.J., Madapallimattan A., Baines A.D. An active pathway for serotonin synthesis by renal proximal tubules // Kidney Int. 1986. V. 29. P. 359–394.
23. Zoccali C., Mallamaci F., Parlongo S. et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease // Circulation. 2002. V. 105. P. 1354–1359.
Review
For citations:
Gilinsky M.A., Anokhin S.I., Zeunova N.A., Koroleva S.A., Latysheva T.V., Petrakova G.M. Blood monoamines in chronic renal failure: effect of hemodialysis. Nephrology and Dialysis. 2009;11(4):310-313. (In Russ.)
Views:
3
Email this article 